Compare Phillips 66 (PSX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Sanofi SA — how do they compare? Phillips 66 trades at $278.18 (market cap $112.36B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Phillips 66 is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Sanofi SA for 94 Days on average.
| PSX | SNY | |
|---|---|---|
Market Cap | $112.36B | $95.18B |
Volume | 2,374,751 | 2,995,646 |
Sector | Energy | Health |
52-Week High | $281.60 | $52.34 |
52-Week Low | $126.76 | $39.51 |
Typical Hold Time | 62 Days | 94 Days |
Enterprise Value | $128.83B | $114.48B |
Dividend Yield | 1.8% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $278.18, up 2.42% with strong technical momentum as it approaches resistance near $280. The stock shows robust fundamentals with a P/E of 16.07 and ROE of 24.02%, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI-driven operational improvements, while analyst consensus remains bullish with a $279 price target.
PSX offers attractive valuation metrics and strong profitability, though revenue declines from 2022-2025 present headwinds. Key risks include refining margin volatility and potential diesel export restrictions. With institutional support and positive earnings trajectory, the stock presents a compelling opportunity for value-oriented investors despite cyclical industry exposure.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
